STRO
Sutro Biopharma, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-1.54
P/S
1.97
EV/EBITDA
-3.13
DCF Value
$-97.62
FCF Yield
-88.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.4%
Operating Margin
-150.2%
Net Margin
-186.5%
ROE
275.3%
ROA
-109.9%
ROIC
-144.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $11.6M | $-46.8M | $-5.45 |
| FY 2025 | $102.5M | $-191.1M | $-22.49 |
| Q3 2025 | $9.7M | $-56.9M | $-6.70 |
| Q2 2025 | $63.7M | $-11.5M | $-1.40 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.31
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.